FDA approves Purdue Pharma’s Palladone
hydrochloride) capsules for the management of persistent moderate
to severe pain in patients requiring continuous opioid pain
relief for an extended period of time.
Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.
Evolocumab holds the FDA's first filed biologics license application for the class.
PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.